---
title: "HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295473527.md"
description: "Q2 2026 saw record revenue and EBITDA growth, driven by leading ophthalmic products and new launches. The dry eye portfolio expanded with TYRVAYA, and multiple pipeline products are set to launch through 2029, supporting strong financial guidance and market leadership.Original document: Harrow, Inc. [HROW] Slides Release — Aug. 11 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-11T02:05:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295473527.md)
  - [en](https://longbridge.com/en/news/295473527.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295473527.md)
generator: "portal-rs"
---

# HROW: Record Q2 2026 revenue and EBITDA growth, with expanded dry eye portfolio and robust pipeline

Q2 2026 saw record revenue and EBITDA growth, driven by leading ophthalmic products and new launches. The dry eye portfolio expanded with TYRVAYA, and multiple pipeline products are set to launch through 2029, supporting strong financial guidance and market leadership.

Original document: Harrow, Inc. \[HROW\] Slides Release — Aug. 11 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [HROWL.US](https://longbridge.com/en/quote/HROWL.US.md)
- [HROWM.US](https://longbridge.com/en/quote/HROWM.US.md)
- [HROW.US](https://longbridge.com/en/quote/HROW.US.md)

## Related News & Research

- [Harrow’s Iheezo Cuts Eye-Injection Discomfort by More Than Half](https://longbridge.com/en/news/296638124.md)
- [Harrow Chief Scientific Officer Amir Shojaei disposes of 11,250 common shares worth $450,000](https://longbridge.com/en/news/296149417.md)
- [Harrow says IHEEZO trial shows 58% lower discomfort than proparacaine after intravitreal injections](https://longbridge.com/en/news/296478792.md)
- [IMM: First-in-class immunotherapies efti and IMP761 advance in oncology and autoimmunity](https://longbridge.com/en/news/296543630.md)
- [Billionaire Stanley Druckenmiller Dumped Micron and Intel, and More Than 11X'd Duquesne Family Office's Stake in an AI Pioneer](https://longbridge.com/en/news/296084502.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**